Dermatitis Clinical Trial
Official title:
Multicenter, Open Label, Uncontrolled Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam in the Management of Some Dermatitis in the Adult
Verified date | January 2022 |
Source | Relife S.r.l. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The scope of this open label clinical trial is to evaluate and confirm the performance of DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology. The disease severity will be clinically measured through the Investigator Global Assessment (IGA) after 28 days of treatment.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 5, 2022 |
Est. primary completion date | January 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject's written informed consent obtained prior to any studyrelated procedures; 2. Generally healthy male and female aged = 18 years; 3. Presence of dermatitis of any typology, including atopic dermatitis (AD), irritant contact dermatitis (ICD) or allergic contact dermatitis (ACD), of mild-moderate severity: - IGA score 2 (=mild) or 3 (=moderate); 4. Dermatitis affecting one or more body areas (face, legs, arms, etc.); 5. Subjects with cooperative attitude, able to comprehend the full nature and the purpose of the investigation, including possible risks and side effects, and able to comply with the requirements of the entire investigation (including ability to attend the planned visits according to the time limits), based on Investigator's judgement. Exclusion Criteria: 1. Severe dermatitis at inclusion; 2. Pregnant and breastfeeding women; 3. Concomitant other skin disorders including skin infections; 4. Currently or previously diagnosed or treated (chemotherapy and/or radiotherapy) for cancer in the past 5 years; 5. History of previous skin cancer (history of non-metastatic squamous or basal cell carcinoma of the skin is allowed); 6. Active infections or use of antibiotics in the past 7 days; 7. Diabetic subjects; 8. History of congenital or acquired immunodepression; 9. Immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, any typology of lupus, rheumatoid arthritis) which could place the subject at risk or interfere with study results; 10. Use of any topic medication for dermatitis in the past 14 days; 11. Use of any topic product for dermatitis in the 2 days before study treatment start; 12. Any systemic treatment or procedure that could influence dermatitis activity within the past 30 days (or 5 half-lives); 13. Use of any corticosteroids, immunosuppressant drugs or immunotherapy within the past 30 days (or 5 half-lives); 14. Use of oral antihistamines and antidepressants in the past 30 days; 15. Subjects with any other clinically significant or unstable concurrent disease or skin condition or general condition that, in the Investigator's opinion, might interfere with the study evaluations; 16. Allergy, sensitivity or intolerance to the components of the investigational device formulations ingredients; 17. Concomitant or previous participation in other interventional clinical study in the past 3 months; 18. Subjects planning sun exposure or tanning booths or UV sources throughout the course of the study. |
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Ospedaliero Universitaria "Federico II" | Napoli | Italia |
Lead Sponsor | Collaborator |
---|---|
Relife S.r.l. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate and confirm the performance of the DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology. | The disease severity will be clinically measured through the Investigator Global Assessment (IGA) for dermatitis after 28 days of treatment. | 28 days of treatment | |
Secondary | to evaluate the performance of the DermoRelizema ecofoam | to evaluate the performance of the DermoRelizema ecofoam in the improvement of dermatitis severity (IGA) after 14 and 42 days of treatment; | after 14 and 42 days of treatment | |
Secondary | to evaluate the eczema | to evaluate the eczema improvement through the EASI (Eczema Area and Severity Index) score | to 14, 28 and 42 days of treatment | |
Secondary | to evaluate the improvement in itching, burning, pain and pruritus at visits | to evaluate the improvement in pain and pruritus at visits, as reported by the subject at visits by VAS (Visual Analogue Scale) | to 14, 28 and 42 days of treatment | |
Secondary | to evaluate improvement in the Quality of Life (QoL) of the subject related to his/her dermatitis, | to evaluate improvement in the Quality of Life (QoL) of the subject related to his/her dermatitis, through the DLQI (Dermatology Life Quality Index) questionnaire; | to 14, 28 and 42 days of treatment | |
Secondary | to evaluate the subject's adherence to treatment. | to evaluate the subject's adherence to treatment, reported on the subject's diary and the product accountability | to 14, 28 and 42 days of treatment | |
Secondary | to evaluate the subject's and Investigator's global evaluation of performance of DermoRelizema ecofoam | to evaluate the subject's and Investigator's global evaluation of performance of DermoRelizema ecofoam by means of a 7-items scale (where 1 = very much improved, 2 = improved, 3 = minimally improved, 4
= no change, 5 = minimally worse, 6 = worse, 7 = very much worse) |
at the end of the study ( day 42) | |
Secondary | to evaluate the subject's overall acceptability of the treatment | to evaluate the subject's overall acceptability of the treatment (which takes into account pleasant or unpleasant feeling with the product and the ease of use), performed by means of a 5-item scale (where 1 = very much satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very much dissatisfied) | at the end of the study ( day 42) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 | |
Completed |
NCT00001150 -
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
|
N/A | |
Withdrawn |
NCT04154033 -
Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
|
Phase 2 | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Completed |
NCT02979210 -
Infant Fecal Insult Study
|
N/A | |
Completed |
NCT02615912 -
A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants
|
N/A | |
Withdrawn |
NCT01125761 -
Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis
|
Phase 3 | |
Withdrawn |
NCT00746382 -
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
|
Phase 2 | |
Terminated |
NCT00176956 -
Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients
|
Phase 3 | |
Completed |
NCT05001139 -
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
|
N/A | |
Completed |
NCT00801502 -
Salmon in Pregnancy Study
|
N/A | |
Completed |
NCT00005781 -
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
|
N/A | |
Completed |
NCT05324618 -
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
|
Phase 4 | |
Recruiting |
NCT06436183 -
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT05891743 -
Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.
|